Affordable Access

Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.

Authors
  • Papoutsaki, Marina
  • Chimenti, Maria-Sole
  • Costanzo, Antonio
  • Talamonti, Marina
  • Zangrilli, Arianna
  • Giunta, Alessandro
  • Bianchi, Luca
  • Chimenti, Sergio
Type
Published Article
Journal
Journal of the American Academy of Dermatology
Publisher
Elsevier
Publication Date
Aug 01, 2007
Volume
57
Issue
2
Pages
269–275
Identifiers
PMID: 17574299
Source
Medline
License
Unknown

Abstract

In our experience, although preliminary, monotherapy with adalimumab 40 mg weekly proved to be an effective and safe treatment for the management of plaque-type psoriasis and psoriatic arthritis, with a rapid onset of action in patients whose disease had been refractory to both conventional and biologic agents.

Report this publication

Statistics

Seen <100 times